KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Deferred Taxes (2021)

AbCellera Biologics (ABCL) has disclosed Deferred Taxes for 1 consecutive years, with $1.2 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Deferred Taxes changed N/A year-over-year to $1.2 million, compared with a TTM value of -$2.0 million through Dec 2021, changed N/A, and an annual FY2023 reading of $2.0 million, up 192.72% over the prior year.
  • Deferred Taxes was $1.2 million for Q4 2021 at AbCellera Biologics, up from -$4.0 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $1.2 million in Q4 2021 and bottomed at -$4.0 million in Q3 2021.